Increased Angiotensin II in the Mesometrial Triangle of a Transgenic Rat Model of Preeclampsia

K. Bridget Brosnihan, Lydia Hering, Ralf Dechend, Mark C. Chappell, Florian Herse

Abstract—The pregnant female human angiotensinogen (hAGN) transgenic rat mated with the male hrenin (hREN) transgenic rat is a model of preeclampsia with increased blood pressure, proteinuria, and placenta alterations of edema and necrosis. The reverse mating of female hREN×male hAGN does not show preeclamptic features. Because the placenta is well-recognized to be a key contributor to the preeclamptic syndrome, our hypothesis is that local angiotensin peptide concentrations found in the placenta and its associated mesometrial triangle of the preeclamptic transgenic rat differ from the reverse mating. We characterized the angiotensin peptide content and the mRNA expression of hREN and hAGN of the mesometrial triangle and the placenta. Three groups of pregnant rats from the matings (Sprague-Dawley×Sprague-Dawley, reverse mating, and female hAGN×male hREN) were studied on day 21 of gestation. In the hAGN×hREN transgenic rat, angiotensin II is significantly increased in the placenta and mesometrial triangle vs Sprague-Dawley (24.2±3.9 vs 8.6±1.5 pg/mg protein; 27.8±5.5 vs 5.6±1.3 pg/mg protein; P<0.05), whereas in the reverse mating angiotensin II is increased in the placenta (19.1±1.7 vs 5.6±1.3 pg/mg protein; P<0.05) but unchanged in the mesometrial triangle (4.2±0.2 vs 8.6±1.5 pg/mg protein). The marked contrast in the expression of angiotensin II in the mesometrial triangle of the preeclamptic model vs the reverse mating suggests that local angiotensin II generated from the maternal parts of the uteroplacental unit may play a critical role in preeclampsia. (Hypertension. 2010; 55[part 2]:562-566.)

Key Words: angiotensinogen ■ fetal □ maternal □ placenta □ preeclampsia □ renin-angiotensin system

Preeclampsia is a common disease of pregnancy that is characterized by hypertension and proteinuria. The disease is generally thought to be associated with abnormal development of the placenta. However, interactions of the placenta or fetus with maternal factors are considered to contribute to the disease. Recent studies have identified strains of transgenic rats¹ and mice,² mutant (p57Kip2-deficient)³ mice, and preexisting borderline maternal hypertensive mice⁴ that show the classic features of preeclampsia, including hypertension, proteinuria, and kidney lesions. These models are important in demonstrating that maternal and feto-placental interactions can initiate this complex disease. However, the mechanisms may vary from preexisting maternal condition, release and elevation of high levels of vasoconstrictors into the circulation arising from the placenta, or placenta pathology.

The pregnant female human angiotensinogen (hAGN) transgenic rat (TGR) mated with the male hrenin (hREN) TGR is a model of preeclampsia with increased blood pressure, proteinuria, and placenta alterations of edema and necrosis.¹ Their circulating levels of human plasma renin concentration (PRC) are elevated during pregnancy,¹ arising from hREN released from the placenta. The reverse mating (RM) of female hREN TGR×male hAGN TGR does not show preeclamptic features. Dams harboring the hREN gene do not have hypertension and proteinuria develop when they are mated with males with hAGN. Although human plasma renin concentration is elevated during pregnancy, hAGN remained undetectable,¹ consistent with its not being released from the placenta. Part of the rationale for the difference in the 2 matings is the species-specific dependency of renin and angiotensinogen for rodent and human proteins and their localization in the placenta and the circulation. Thus, single TGR with either hAGN or hREN are normotensive. When the female hAGN mates with the male hREN, active renin of placenta or of fetal origin is secreted and interacts with circulating hAGN in the dams to produce increased circulating angiotensin (Ang) II. However, with the RM, hAGN remains undetectable in the circulation, indicating that it is not secreted from the placenta¹ and overproduction of Ang II in the circulation does not occur. Although the preeclamptic model is viewed as a high circulating Ang II model that arises from overproduction of hREN from the placenta, the function and regulation of the renin-angiotensin system (RAS) in the uteroplacental unit is unknown.

The rodent has a hemochorial type of placenta that is apposed to a well-decidualized endometrium.⁵ The placenta...
consists of the labyrinth, trophospongium, and giant cell layers, which are of fetal origin. The labyrinth layer comprises the major portion of the placental disc, has very thin fetal capillaries surrounded by trophoblast cells, and constitutes the major site of maternal/fetal exchange. The trophospongium layer has uniform cells that are precursors of differentiated trophoblast cells. Associated with the placenta is the mesometrial triangle (MT) that consists of decidualized cells and numerous loops of spiral arteries. This area can be considered an expansion of the decidua or a deeper part of the placenta bed (maternal origin). Trophoblast invasion occurs in both the decidua and MT in the rat, a characteristic that Pijnenborg et al. propose makes it a suitable model for human pregnancy.

With the 2 types of TGR matings, the genetic composition of the uteroplacental unit may be quite different between tissues of fetal and maternal origin. A paternal expression of the uteroplacental unit may be quite different between pregnancy. Female components of the utero-placental unit. Our objective was to peptide content of the fetal (placenta) and maternal (MT) whether preeclampsia occurs, we characterized the Ang genes of the dams would be present; however, it is possible for the fetal genes to be present depending on the degree of invasion of the trophoblast cells, which are of fetal origin. Because the maternal influence may be critical in determining whether preeclampsia occurs, we characterized the Ang peptide content of the fetal (placenta) and maternal (MT) components of the utero-placental unit. Our objective was to determine if there is a difference in angiotensin peptide concentrations found in the MT and placenta of pregnant preeclamptic transgenic rats resulting from the mating of the female hAGN TGR mated with the male hREN as compared to the RM or normal Sprague-Dawley (SD) pregnant rats. The rationale and relevance for conducting studies in this animal model may reside in our recent demonstration showing that both the uterine maternal placenta bed and the chorionic villi of preeclamptic women had markedly elevated Ang II concentrations. This finding would suggest that activation of the RAS in both the maternal and fetal components of the utero-placenta unit may be important contributors to the human disease.

Materials and Methods

For these studies, frozen tissue was received from Drs Dechend, Hering, and Herse from Experimental and Clinical Research Center, Berlin, Germany. These tissues were obtained from animals described in previous publications. Rat placenta with the attached MT were collected from a preeclampsia rat model (female TGR hAGN × male TGR hREN; n = 4), the RM (female TGR hREN × male TGR hAGN; n = 5), which did not show signs of preeclampsia, and age-matched control rats (SD×SD; n = 4) at day 21 of pregnancy. The MT and the proximal part of the mesometrium were dissected away from the placenta. Placenta and MT were separated and snap-frozen for mRNA and peptide measurements. For peptide measurements, 4 to 5 MT and placenta from the same animal were pooled. Tissues were stored at −80°C until used. Local authorities (LAGeSo) approved the animal protocol that complied with criteria outlined by the American Physiological Society.

Total mRNA was isolated with the Qiagen RNeasy Mini Kit according to the manufacturer’s protocol and as described. Quality and quantity were checked by NanoDrop (Pepslab) and Bioanalyzer (Agilent Technologies); 2 μg of total RNA was reverse-transcribed into cDNA by using the Transcriptor First Strand cDNA synthesis Kit from Roche Diagnostics and were analyzed for hAGN, hREN, rAGN, rREN, and 18S by real-time quantitative polymerase chain reaction on ABI 5700 sequence detection system (PE Biosystems). Primer and probes were designed with PrimerExpress 2.0 (Applied Biosystems).

For Ang peptides analysis, tissue were homogenized in acid/ethanol (80% vol/vol 0.1 N HCl) containing a cocktail of protease inhibitors including 0.44 mmol/L 1,20 orho-phenanthroline monohydrate, 0.12 mmol/L, pepstatin, 1 mmol/L Na p-hydroxymercuribenzoate, 15% EDTA, and 0.01 mmol/L WFM-1, a rat renin inhibitor, centrifuged at 12 000 rpm for 20 minutes at 4°C and stored overnight at 4°C, as previously described. Samples were centrifuged at 12 000 rpm for 20 minutes at 4°C, and supernatant was removed and added to 1% n-Heptfluorobutyric acid and refrigerated overnight at −20°C. The supernatant was extracted using Sep-Pak columns activated with 5 mL wash of a mixture of n-Heptfluorobutyric acid:methanol (0.1%:80%) and sequential washes of 0.1% n-Heptfluorobutyric acid. After the sample was applied to the column, it was washed with 0.1% n-Heptfluorobutyric acid and followed with a water wash. The sample was eluted with 3.3 mL washes of a mixture of acid methanol (0.1%:80%). The sample was eluted, reconstituted, and split for 2 radioimmunoassays. Recoveries of radiolabeled Ang II were followed and samples were corrected for recoveries. Ang I was measured by a kit from Peninsula and Ang II was measured by a kit from Alpco. The minimum detectable levels of the assays were 1 and 0.8 fmol/mL for Ang I and Ang II, respectively. The ina-assay and interassay coefficients of variation were 18% and 22% for Ang I and 8% and 22% for Ang II.

Data are presented as means±SEM. We tested Kolmogorov-Smirnov for distribution. For group differences we tested 1-way ANOVA with Scheffe post hoc test, Dunnett T3 or Kruskal-Wallis test, and Mann-Whitney U test as appropriate. A value of P<0.05 was considered statistically significant.

Results

The Table shows that the preeclamptic model (hAGN×hREN) had significantly higher mean arterial blood pressure and albuminuria and significantly lower fetal body weight and placenta weight as compared to the RM and SD pregnant rats. Figure 1 shows the levels of Ang I and Ang II in the MT and placenta of the 3 groups of pregnant rats. Ang I and Ang II levels were similar in the MT and placenta of the SD pregnant rat. In the preeclamptic model (hAGN×hREN), Ang II was significantly increased in both MT (24.2±3.9 vs 8.6±1.5 pg/mg protein; P<0.05) and placenta (27.8±5.5 vs 5.6±1.3 pg/mg protein; P<0.05) as compared to SD. In the RM, Ang II was increased in the placenta (19.1±1.7 vs 5.6±1.3 pg/mg protein; P<0.05) but unchanged in the MT (4.2±0.2 vs 8.6±1.5 pg/mg protein; not significant). There was no difference between the levels of Ang II in the placenta between the preeclamptic and RM pregnant groups. A similar pattern was observed for Ang I (Figure 1).

<table>
<thead>
<tr>
<th>Table. Phenotype of Pregnant Animal Models</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics</td>
</tr>
<tr>
<td>MAP, mm Hg</td>
</tr>
<tr>
<td>Albuminuria, mg/d</td>
</tr>
<tr>
<td>Fetal body weight, g</td>
</tr>
<tr>
<td>Placenta weight (with MT), g</td>
</tr>
<tr>
<td>Fetal brain-to-liver ratio</td>
</tr>
</tbody>
</table>

Values are means±SEM. *P<0.01 hAGN×hREN vs SD and RM.
Figure 1. Angiotensin peptides in the uteroplacental unit of normal pregnant (SD) and pregnant TGR resulting from the mating of female hAGN<sup>x</sup>male hRen (preeclamptic model) and the RM. Ang I and Ang II are significantly increased in both the MT and placenta in the preeclamptic model as compared to SD. In the RM, Ang II is increased in the placenta but not in the MT. Ang II is significantly higher in the MT of the preeclamptic vs the RM. Values are mean±SEM. *<p><0.05 vs SD. *<p><0.05 between groups as indicated.

Figure 2 shows the expression of hREN and hAGN in the 3 groups of pregnant rats. As expected, hREN and hAGN mRNA are not expressed in pregnant SD rats. The preeclamptic model and the RM have both hREN mRNA and hAGN mRNA in the MT and placenta. However, the preeclamptic model has significantly higher levels of hAGN mRNA in the MT compared to the RM (>-400-fold increase). The hREN mRNA in the MT is only weakly expressed compared to the placenta in both matings.

Figure 3 shows the expression of rREN and rAGN in the 3 groups of rats. The rREN mRNA and rAGN mRNA are expressed in all 3 groups and in both MT and placenta. In the preeclamptic model and in the RM, there was downregulation of rREN mRNA in the MT as compared to SD.

Discussion

Our study revealed that the placenta of both matings showed marked elevations in Ang II that arise from the expression of both hREN and hAGN mRNA. The major finding of our study was the contrast in the expression of Ang II in the MT of the preeclamptic model vs the RM. In the MT from the preeclamptic TGR, Ang II was markedly elevated in association with the expression of both hREN and hAGN mRNA, whereas in the RM Ang II in the MT was not elevated, in association with substantially reduced expression of hAGN as compared to the preeclamptic mating. Our study provides evidence of 2 separate and differentially expressed local RAS in the MT and placenta. Because Ang II was elevated in the MT of the preeclamptic and not in the RM, the findings suggest that local actions of Ang II in the MT, influencing trophoblast invasion, survival, and blood vessel remodeling, may be critical in contributing to the preeclamptic pathophysiology.

The very low expression of hAGN in the MT parallels the lack of detectable hAGN in the circulation of the RM. In the RM, the endogenous hREN activity in the circulation was unaccompanied by hAGN protein, which was not released from the placenta into the maternal circulation. The lack of change of Ang II in the MT of the RM would suggest that hAGN from the placenta also is not released into the MT or transported in with the trophoblasts. However, in the preeclamptic TGR, plasma hREN concentration and circulating hAGN increased in late gestation, with the hREN arising from release from the placenta.

Our studies suggest that renin is released from the placenta because of the marked difference in expression of hREN in the placenta and MT. The placental
The MT consists of a mass of decidualized cells, uterine natural killer cells, and many loops of spiral arteries. In the rat, trophoblast cells from the placenta proliferate, migrate, and invade into the MT, the decidua, and the uterine vasculature. The fetal cells invade the maternal decidua and remodel the spiral arteries by replacing the endothelial layers of these vessels. The remodeled vessels promote an increase in blood flow, which promotes the delivery of nutrients and oxygen to the developing fetus. However, the long-held view is that preeclampsia arises from shallow trophoblast invasion and a reduced number of remodeled spiral arteries in the decidua, resulting in ischemia of the vessels. Our findings in the MT must be assessed in light of a previous study characterizing endovascular trophoblast invasion and spiral artery remodeling in the preeclamptic and RM transgenic rat models. Contrary to the hypothesis and evidence in human preeclampsia that there is restricted endovascular trophoblast invasion and spiral artery remodeling in the myometrium, Geusens et al showed that the transgenic preeclamptic rats had deeper endovascular trophoblast invasion in the MT than the RM and SD controls. Because zygote-derived trophoblasts invade the MT, their presence in the MT would be consistent with the expression of both hREN and hAGN genes, reflecting both the maternal and paternal contribution to the augmented production of Ang II in both the MT and the placenta. The lower expression of hREN in the MT may not be a limiting factor in the production of Ang II, because it has been shown that renin protein can be released into the circulation from the placenta in these animals. Furthermore, our finding of increased Ang II in the preeclamptic model in both the MT and placenta is consistent with our recent characterization of the RAS in human chorionic villi and maternal placenta bed of preeclamptic subjects, which demonstrated that Ang II was increased in both beds. The pattern of gene regulation contributing to the increased Ang II differed in the 2 local beds, with high AGN mRNA being found in the chorionic villi and high REN mRNA being found in the maternal placenta bed. Herse et al showed that components of tissue RAS are much higher in the maternal decidua than in the fetal parts of the placenta, suggesting a role for the RAS in trophoblast–decidua interaction. These latter findings, together with the differential expression in the MT and placenta of matings of both TGR, support the presence of independent local RAS systems in fetal placenta and its associated maternal MT tissues.

With the reverse mating, Geusens et al showed that there were fewer trophoblasts present in the MT and that they invaded to a lesser degree as compared to the preeclamptic model. The findings of very-low-expression hREN and hAGN in the MT of the RM are consistent with the MT levels of Ang II that are not different from the control pregnant rats. In the MT of the RM, hAGN mRNA was 400-fold lower than in the preeclamptic model. A number of possibilities can be offered to explain the low levels of hAGN in the MT. First, the fewer number of trophoblasts that invade resulted in lower levels of hAGN mRNA. Second, there is downregulation of hAGN gene expression in the MT of the reversible mating TGR. In both cases, the hAGN would not be sufficient to be translated into hAGN protein and thus could not interact with hREN protein present in the maternal tissue to form Ang II. A third possibility is based on studies in a similar model of preeclampsia in transgenic mice conducted by Takimoto-Ohnishi et al who showed using in situ hybridization that hREN is expressed in trophoblasts. This finding suggests that there may be cell-type-specific expression of hAGN and hREN. In the case of the RM, which has low maternal expression of hREN in the MT, if invading trophoblasts express only hREN, then there would be no additional Ang II generation because hAGN would not be provided by the fetal trophoblast cells.

In the SD pregnant rat, we showed that both the MT and the placenta express rREN and rAGN mRNA; this was associated with equivalent amounts of Ang I and Ang II in both. As expected, there is no hREN or hAGN mRNA present. The most striking finding was the profound down-regulation of rREN mRNA in the MT in both TGR matings. This occurred with no change in rAGN mRNA in the MT in both matings. Because blood pressure and the levels of Ang II are different in the MT of the preeclamptic and RM, it is
not likely that either Ang II or blood pressure, 2 well-characterized regulators of renal renin, are responsible for the downregulation of rREN in this tissue. To understand the regulation of the rREN mRNA in the MT, consideration of local cytokines, growth factors, or hormones released from or into the MT need to be explored.

In conclusion, in the preeclamptic TGR model there are 2 locally activated RAS in the placenta (fetal origin) and its associated maternal MT (maternal origin) attributable to the expression of hAGN and hREN in association with elevated Ang II. In the RM, the low level of expression hAGN and hREN in the MT is consistent with the low levels of Ang II. The contrast in the production of Ang II in the MT of the preeclamptic model vs the RM suggests a local action of the elevated Ang II in the MT that would influence trophoblast invasion and survival and the extent of blood vessel remodeling that may contribute to the pathophysiology of preeclampsia.

**Perspective**

The placenta is a highly specialized organ that plays an essential role in fetal growth and development. The local placental RAS acts in an autocrine/paracrine way and is thought to be involved in increasing vascular permeability, angiogenesis, and decidualization during implantation and placental development. This study highlights the distinctness of fetal and maternal utero-placental RAS components and the interactions that may arise in these local environments. In these transgenic models, the paternal influence was critical in determining the characteristics of the maternal environment. In the case of the preeclamptic model, the paternal hREN gene was expressed in both the placenta and MT, resulting in an activated RAS in both. Theses findings are similar to the activation of local Ang II in fetal and maternal tissues of the uteroplacental unit in human preeclampsia. Understanding the local maternal environment and its influence on the placenta appears to be critical in preeclampsia.

**Sources of Funding**

This work was supported in part by grants from the National Institutes of Health (NHLBI-P01, HL51952) and the Deutsche Forschungsgemeinschaft (DE631-1). The authors gratefully acknowledge grant support in part provided by Unifi, Inc, Greensboro, N.C., and Farley-Hudson Foundation, Jacksonville, N.C.

**Disclosures**

None.

**References**


Increased Angiotensin II in the Mesometrial Triangle of a Transgenic Rat Model of Preeclampsia

K. Bridget Brosnihan, Lydia Hering, Ralf Dechend, Mark C. Chappell and Florian Herse

Hypertension. 2010;55:562-566; originally published online December 28, 2009; doi: 10.1161/HYPERTENSIONAHA.109.145656

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/55/2/562

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/